Rousselot Secures U.S. Patent for Nextida GC, a First-of-Its-Kind Collagen Peptide for Post-Meal Blood Glucose Support
核心洞察
The U.S. Patent and Trademark Office granted Patent No. US12636339 to Rousselot for Nextida GC (搜索), a novel collagen peptide composition targeting healthy post-meal blood glucose levels.
The patent covers both the production process and use of Nextida GC (搜索) as a dietary supplement ingredient, offering a non-pharmaceutical option for metabolic support.
International patents have also been secured in Australia, Europe, Japan, and China, with additional applications pending across seven other countries.
Darling Ingredients (搜索)' health brand Rousselot has strengthened its foothold in the metabolic health market after the U.S. Patent and Trademark Office (USPTO) granted Patent No. US12636339 for Nextida GC (搜索), a first-of-its-kind collagen peptide composition developed to support healthy after-meal blood glucose levels. The patent, announced on June 3, 2026, protects both the production process and the use of Nextida GC as a dietary supplement ingredient, marking a significant milestone for the company as consumer demand accelerates for natural, non-pharmaceutical approaches to metabolic wellbeing.
"This patent reinforces the scientific foundation behind Nextida GC (搜索) and highlights Darling Ingredients (搜索)' ability to translate its collagen expertise into targeted health solutions," said Randall C. Stuewe, Chairman and Chief Executive Officer of Darling Ingredients. "As demand grows for natural, non-pharmaceutical approaches to health and wellness, we are strengthening our leadership in collagen peptide health ingredients while building a broader pipeline of Nextida solutions."
A Novel Approach to Metabolic Support
Nextida GC (搜索) is formulated to support healthier after-meal glucose responses, offering supplement brands a collagen-based approach to metabolic support. The ingredient is positioned as a non-pharmaceutical option for managing blood glucose through science-backed nutrition, catering to the rapidly expanding category of metabolic health supplements.
The product forms part of Rousselot's expanding Nextida portfolio, which is being developed to address distinct functional health needs through precision-engineered collagen peptides. The company describes Nextida GC (搜索) as a collagen peptide composition formulated specifically for dietary supplement applications related to natural glucose control and metabolic support.
Global Patent Protection
The U.S. patent adds to a growing list of international protections for Nextida GC (搜索). Authorities in Australia (AU2023279850B2), Europe (EP4498839B1), Japan (JP7751755B2), and China (CN119212574B) have already granted patents for the ingredient. Additional patent applications remain pending across Brazil, Canada, Colombia, Korea, Mexico, India, and Peru.
The breadth of international recognition reflects both the novelty of the ingredient and the rising strategic importance of collagen peptides in the global health-and-wellness sector. With metabolic health emerging as one of the fastest-growing supplement categories, Rousselot's newly patented technology positions the company at the forefront of science-backed nutritional solutions designed to meet consumer demand for natural, effective, and clinically grounded products.
Company Background
Rousselot, the health brand of Darling Ingredients (搜索), is a global leader in gelatin- and collagen-based solutions serving the food, health and nutrition, biomedical, and pharmaceutical industries. Darling Ingredients operates over 260 facilities in more than 15 countries, processes approximately 15% of the world's animal agricultural by-products, and produces about 30% of the world's collagen, encompassing both gelatin and hydrolyzed collagen.